[Apolipoprotein E4, a Genetic Risk Factor for Alzheimer's Disease]
Masataka Kikuchi1, Akihiro Nakaya
1Department of Genome Informatics, Graduate School of Medicine, Osaka University.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|October 8, 2019
Summary
Apolipoprotein E (APOE) is a key genetic risk factor for Alzheimer's disease (AD). This review explores APOE's functions and its newly discovered diverse roles in the brain contributing to AD.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Apolipoprotein E (APOE) is a significant genetic risk factor for Alzheimer's disease (AD).
- Existing knowledge of APOE functions is insufficient to fully explain the observed AD pathologies.
- Understanding APOE's multifaceted roles is crucial for AD research.
Purpose of the Study:
- To review the historical and known functions of Apolipoprotein E (APOE).
- To elucidate the recently discovered pleiotropic roles of APOE in the brain.
- To provide a comprehensive understanding of APOE's contribution to Alzheimer's disease.
Main Methods:
- Literature review of historical and recent scientific publications on APOE.
- Analysis of genetic studies linking APOE to Alzheimer's disease.
- Synthesis of current research on APOE's diverse functions in the central nervous system.
Main Results:
- APOE's established roles in lipid transport and metabolism.
- Emerging evidence highlights APOE's involvement in neuroinflammation, synaptic function, and amyloid-beta clearance.
- APOE exhibits pleiotropic effects beyond its classical functions, impacting various AD pathologies.
Conclusions:
- APOE's complex and diverse functions are critical to understanding Alzheimer's disease pathogenesis.
- Further research into APOE's pleiotropic roles is essential for developing effective AD therapeutics.
- A comprehensive view of APOE is necessary to fully explicate its impact on AD.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736


